Hidehito Horinouchi
National Cancer Center Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hidehito Horinouchi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:39 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05211895 · A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCAstraZeneca · active not recruiting · Non-Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:39 UTC. The ranking covers the 200 most relevant of 46 PubMed records, and a shared surname and initials can bring in a namesake. All 46 on PubMed
- Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2024424 citationsRCR 50.7
- Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung.Lung Cancer · 2003218 citationsRCR 6.0
- 181 citationsRCR 20.1
- Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.Eur J Cancer · 2019126 citationsRCR 4.5
- 84 citationsRCR 2.3
- Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.Eur Respir J · 202284 citationsRCR 6.7
- 65 citationsRCR 2.4
- Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.Cancer Sci · 202161 citationsRCR 2.7
- 54 citationsRCR 10.7
- Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study.Jpn J Clin Oncol · 201353 citationsRCR 1.8